Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CompumedicsASX:CMP -14.55%49 Price-to-Operating-Cash-Flow is 7.12 as of Sep. 03, 2026, which is 77% below its 10-year median of 30.38. GuruFocus rates ASX:CMP with a GF Score™ of 49/100 and a GF Value™ of A$0.30 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 492 Medical Devices & Instruments companies, Compumedics ranks better than 82.93% on this metric.
As of today (2026-09-03), Compumedics's share price is A$0.235.
Compumedics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.03. Hence, Compumedics's Price-to-Operating-Cash-Flow Ratio for today is 7.12.
The historical rank and industry rank for Compumedics's Price-to-Operating-Cash-Flow or its related term are showing as below:
ASX:CMP'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.68 Med: 30.38 Max: 225
Current: 7.13
During the past 13 years, Compumedics's highest Price-to-Operating-Cash-Flow Ratio was 225.00. The lowest was 3.68. And the median was 30.38.
ASX:CMP's Price-to-Operating-Cash-Flow is ranked better than 82.93% of 492
companies
in the Medical Devices & Instruments industry
Industry Median: 17.84
vs ASX:CMP: 7.13
Compumedics's Cash Flow from Operations per share for the
six
months ended in Jun. 2026 was A$0.02.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.03.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Compumedics was 1550.00% per year.
During the past 13 years, Compumedics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 89.50% per year. The lowest was -53.60% per year. And the median was 3.85% per year.
Compumedics Price-to-Operating-Cash-Flow Related Terms
Compumedics Price-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for Compumedics's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CMP vs ABT, SYK, MDT: Price-to-Operating-Cash-Flow Comparison
For the Medical Devices subindustry, Compumedics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compumedics Price-to-Operating-Cash-Flow vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Compumedics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Compumedics's Price-to-Operating-Cash-Flow falls into.
Compumedics's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio
=
Share Price
/
Cash Flow from Operations per share (TTM)
=
0.235
/
0.033
=
7.12
Compumedics's Share Price of today is A$0.235.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Compumedics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Price-to-Operating-Cash-Flow of 7.12 mean?
Compumedics (ASX:CMP) has a Price-to-Operating-Cash-Flow of 7.12 as of Sep. 03, 2026. Price-to-operating-cash-flow ratio is the ratio of share price to a company's per-share cash from operations. View historical data on Compumedics and its competitors. This is 77% below median its historical median of 30.38. Over the past decade, Compumedics' Price-to-Operating-Cash-Flow has ranged from 3.68 to 225.00. According to the industry distribution chart, Compumedics ranks #84 out of 492 companies in the Medical Devices & Instruments industry, placing it in the top 17.1%.
Is Compumedics' Price-to-Operating-Cash-Flow too high?
Compumedics' current Price-to-Operating-Cash-Flow of 7.12 is 77% below median its 10-year median of 30.38. Over the past 10 years, this metric has ranged from a low of 3.68 to a high of 225.00. The Medical Devices & Instruments industry median Price-to-Operating-Cash-Flow is 17.84. Compumedics' value of 7.12 is 60.1% below this industry median. Based on the distribution chart, Compumedics ranks #84 out of 492 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Compumedics has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Compumedics' Price-to-Operating-Cash-Flow compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Compumedics ranks #84 out of 492 companies for Price-to-Operating-Cash-Flow. This places Compumedics in the top 17% of its industry — outperforming the majority of peers. The industry median Price-to-Operating-Cash-Flow is 17.84. Compumedics' value of 7.12 is 60.1% below this benchmark. Historically, Compumedics' own Price-to-Operating-Cash-Flow has ranged from 3.68 to 225.00 over the past decade. While the company's 10-year median is 30.38 vs. the industry median of 17.84, Compumedics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Operating-Cash-Flow for a Medical Devices & Instruments company?
The median Price-to-Operating-Cash-Flow among Medical Devices & Instruments companies is 17.84, based on 492 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compumedics's current Price-to-Operating-Cash-Flow of 7.12 is 60.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Operating-Cash-Flow mean?
A high Price-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Price-to-operating-cash-flow ratio is the ratio of share price to a company's per-share cash from operations. View historical data on Compumedics and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Operating-Cash-Flow is 17.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compumedics's current Price-to-Operating-Cash-Flow is 7.12, which is 77% below median its own 10-year median of 30.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compumedics stock overvalued right now?
Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.30, compared to a current price of A$0.24 — trading 21.7% below its estimated fair value. The current Price-to-Operating-Cash-Flow is 7.12, which is 77% below median its 10-year median of 30.38 and 60.1% below the Medical Devices & Instruments industry median of 17.84. Compumedics' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Operating-Cash-Flow calculated?
Price-to-Operating-Cash-Flow is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current Price-to-Operating-Cash-Flow is 7.12 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Compumedics (ASX:CMP) Overvalued in 2026?
Based on GuruFocus' analysis, Compumedics stock appears to be undervalued.
The current stock price of A$0.24 is trading 21.7% below its estimated GF Value™ of A$0.30.
GuruFocus considers Compumedics to be Modestly Undervalued.
Key valuation signals for ASX:CMP:
Price-to-Operating-Cash-Flow: 7.12 (77% below median its 10-year median of 30.38)
GF Value™: A$0.30 vs. price of A$0.24 (21.7% below fair value)
Industry Position: 60.1% below the Medical Devices & Instruments median (#84 of 492)
No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
49GF Score
Get the complete analysis for ASX:CMP
Price-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMP has been successfully added to your 
